# Efficacy and Safety of Once-Weekly SHR-3167 Compared With Once-Daily Insulin Glargine in Adults With Insulin-Naive Type 2 Diabetes

Study · id `cardio:ct-nct07920939` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07920939](<https://clinicaltrials.gov/study/NCT07920939>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT07920939

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 450 participants.

## Technical summary

Registry record NCT07920939. Randomized; no masking; primary purpose treatment. Start 2026-11 (anticipated); primary completion 2027-10 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 450 participants (planned count; ClinicalTrials.gov record NCT07920939, source copy `cardio:ctgov-nct07920939-2026-11-06`, retrieved 2026-11-18)
- Planned start: 2026-11 (anticipated) (ClinicalTrials.gov record NCT07920939, source copy `cardio:ctgov-nct07920939-2026-11-06`, retrieved 2026-11-18)
- Primary completion: 2027-10 (anticipated) (ClinicalTrials.gov record NCT07920939, source copy `cardio:ctgov-nct07920939-2026-11-06`, retrieved 2026-11-18)
- Completion: 2028-07 (anticipated) (ClinicalTrials.gov record NCT07920939, source copy `cardio:ctgov-nct07920939-2026-11-06`, retrieved 2026-11-18)
- Countries: China (ClinicalTrials.gov record NCT07920939, source copy `cardio:ctgov-nct07920939-2026-11-06`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07920939-2026-11-06`, retrieved 2026-11-18)

## The registry's words

- Brief title: Efficacy and Safety of Once-Weekly SHR-3167 Compared With Once-Daily Insulin Glargine in Adults With Insulin-Naive Type 2 Diabetes
- Condition: Type 2 Diabetes
- Intervention (Drug): SHR-3167 Injection
- Intervention (Drug): Insulin glargine (IGlar)
- Lead sponsor: Jiangsu HengRui Medicine Co., Ltd.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Jiangsu HengRui Medicine Co., Ltd. (`cardio:org-jiangsu-hengrui-medicine-co-ltd`)

## Provenance

Content hash: 6fc74d5b1743e78b28b4a8a8c46a47a4f3f8889212191195e7011cf01a6e6db8
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
